natgillin/translations-raw huggingface dataset:
Anaemia (haemoglobin &lt; 10 g/dl) was reported in 7% and 14% of patients treated with Pegasys monotherapy or in combination therapy, respectively.
Anemija (hemoglobin &lt; 10g/dl) je zabilježena u 7% bolesnika koji su primali samo Pegasys odnosno u 14% bolesnika koji su primali kombinirano liječenje.
Anaemia (haemoglobin &lt; 9.4 g/dL) was reported in 12 % (23/194) of patients treated with ribavirin in combination with peginterferon alfa-2b.
Anemija (hemoglobin &lt; 9,4 g/dl) je prijavljena u 12% (23/194) bolesnika liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b.
Anaemia (haemoglobin &lt; 9.4 g/dl) was reported in 12% (23/194) of patients treated with ribavirin in combination with peginterferon alfa-2b.
Anemija (hemoglobin &lt; 9,4 g/dl) je prijavljena u 12 % (23/194) bolesnika liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b.
Anaemia (haemoglobin &lt; 8.0 g/dl) occurred in 100% of patients.
Anemija (hemoglobin &lt; 8,0 g/dl) se pojavila u 100% bolesnika.
Anaemia (haemoglobin &lt; 8.0 g/dl) occurred in 69% of patients.
Anemija (hemoglobin &lt; 8,0 g/dl) se pojavila u 69% bolesnika.
Anaemia (Hb &lt; 10 g/dl) was observed in 46% of patients on Abraxane, and was severe (Hb &lt; 8 g/dl) in three cases.
Anemija (Hb &lt; 10 g/dl) je opažena u 46% bolesnika koji su primali Abraxane i bila je teška (Hb &lt; 8 g/dl) u tri slučaja.
Anaemia (hemoglobin &lt; 9.4 g/dl) was reported in 12 % (23/194) of patients treated with PegIntron in combination with ribavirin.
Anemija (hemoglobin &lt; 9,4 g/dl) je prijavljena u 12% (23/194) bolesnika liječenih lijekom PegIntron u kombinaciji s ribavirinom.
Anaemia (hemoglobin &lt; 9.4 g/dl) was reported in 12 % (23/194) of patients treated with ViraferonPeg in combination with ribavirin.
Anemija (hemoglobin &lt; 9,4 g/dl) je prijavljena u 12% (23/194) bolesnika liječenih lijekom ViraferonPeg u kombinaciji s ribavirinom.
Anaemia a (haemoglobin &lt; 9.4 g/dl) was reported in 12 % (23/194) of patients treated with ribavirin in combination with peginterferon alfa-2b.
Anemija (hemoglobin &lt; 9,4 g/dl) je prijavljena u 12% (23/194) bolesnika liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b.
Analyses for both primary and secondary endpoints on various subgroups including age ( &lt; 65 years and ≥ 65 years); race (White and Non-White); region (North America, Europe, Middle East and Africa, and Asia Pacific); baseline corticosteroid use (yes and no); prior therapy (yes and no); and MCD histology (plasmatic and mixed histology) consistently showed that the treatment effect favoured the siltuximab arm except for the hyaline vascular subgroup in which no patient achieved the definition of the primary endpoint.
Analiza i primarnih mjera ishoda i sekundarnih mjera ishoda za različite podskupine uključujući dob ( &lt; 65 godina i ≥ 65 godina); rasu (bijelu i ostale); regiju (Sjeverna Amerika, Europa, Bliski istok i Afrika, te azijsko-pacifička regija); primjenu kortikosteroida na početku (da ili ne); prethodnu terapiju (da ili ne); i MCD histologiju (plazmocitni i miješani histološki podtip) dosljedno je pokazala da je učinak liječenja u korist skupine liječene siltuksimabom osim za podskupinu hijalinsko vaskularnog histološkog podtipa u kojoj niti jedan bolesnik nije postigao definiranu primarnu mjeru ishoda.
Analysis of the composite endpoint in the All ACS population (combined UA/NSTEMI and STEMI cohorts) was contingent on showing statistical superiority of prasugrel versus clopidogrel in the UA/NSTEMI cohort (p &lt; 0.05).
Analiza objedinjenog ishoda u populaciji svih bolesnika s akutnim koronarnim sindromom (združene UA/NSTEMI i STEMI kohorte) ovisila je o dokazivanju statističke superiornosti prasugrela u odnosu na klopidogrel u kohorti bolesnika koji su imali UA/NSTEMI (p &lt; 0,05).
ANC 1,000 to &lt; 1,500/mm3
ABN 1000 do &lt; 1500/mm3
ANC 500 to &lt; 1,000/mm3
ABN 500 do &lt; 1000/mm3
ANC &lt; 0.5
ABN &lt; 0,5
ANC &lt; 0.5 x 109/l
ABN &lt; 0,5×109/l
ANC &lt; 0.5 x 109/l lasting more than 7 days
ABN &lt; 0,5 x 109/l traje dulje od 7 dana
ANC &lt; 1 x 109/l neutropenia complicated by fever or infection
ABN &lt; 1 x 109/l neutropenija komplicirana vrućicom ili infekcijom
ANC &lt; 1.0 x 109/l
ABN &lt; 1,0 x 109/l
ANC &lt; 1.0 x 109/L and/or platelets &lt; 50 x 109/L
ABN &lt; 1,0 x 109/l
ANC &lt; 1.0 x 109/L and/or platelets &lt; 50 x 109/L
ABN &lt; 1,0 x 109/l i/ili trombociti &lt; 50 x 109/l
ANC &lt; 500/mm3
ABN &lt; 500/mm3
ANC &lt; 1.0x109/1
aABN &lt; 0,5 x 109/l
ANC &lt; 1.0x109/1
ABN &lt; 1,0 x 109/l
ANC &lt; 1.0x109/l
ABN &lt; 1,0 x 109/l
ANC &gt; 1
ABN &gt; 1
ANC &gt; 1.0 x 109/L for 3 consecutive days
ABN &gt; 1,0x109/l tijekom 3 uzastopna dana
ANC &gt; 1.0 x 109/L for 3 consecutive days
ABN &gt; 1,0 x 109/l tijekom 3 uzastopna dana
ANC* &lt; 0.5 x 109/l or Febrile neutropenia (fever ≥38.5°C and ANC
ABN* &lt; 0,5 x 109/l ili febrilna neutropenija (vrućica ≥38,5°C i ABN
ANC* &lt; 0.5 x 109/l or Febrile neutropenia (fever ≥38.5°C and ANC &lt; 1 x 109/l)
ABN* &lt; 0,5 x 109/l ili febrilna neutropenija (vrućica ≥38,5°C i ABN
ANC* &lt; 1.0 x 109/L or
ABN* &lt; 1,0 x 109/l
ANC* &lt; 0.5 x 109/l and/or platelet counts &lt; 10 x 109/l
ABN* &lt; 0,5 x 109/l i/ili broj trombocita &lt; 10 x 109/l
ANC* &lt; 1.0 x 109/l and/or platelet counts &lt; 50 x 109/l
ABN* &lt; 1,0 x 109/l i/ili broj trombocita &lt; 50 x 109/l
ANC* &lt; 1.0 x 109/l and/or platelet counts &lt; 50 x 109/l
ABN* &lt; 1,0 x 109/l i/ili trombociti &lt; 50 x 109/l
ANCa &lt; 1.0×109/L
ABNa &lt; 1,0×109/l
and Hb increase &lt; 1 g/dl
i povećanje Hb &lt; 1 g/dl
and/or platelets &lt; 10 x 109/L
aABN &lt; 0,5 x 109/l i/ili trombociti &lt; 10 x 109/l
and/or platelets &lt; 10 x 109/l
i/ili trombociti &lt; 10 x 109/l
and/or platelets &lt; 10 x 109/l
i/ili trombociti &lt; 10×109/l
and/or platelets &lt; 50 x 109/l
i/ili trombociti &lt; 50 x 109/l
and/or platelets &lt; 50 x 109/l
i/ili trombociti &lt; 50×109/l
and/or platelets &lt; 50x109/1
i/ili trombociti &lt; 10 x 109/l
and/or platelets &lt; 50x109/l
i/ili trombociti &lt; 50 x 109/l
ANGELINI PHARMA HELLAS ABEE ΠΑΡΑΓΩΓΗΣ &amp; ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ
ANGELINI PHARMA HELLAS ABEE ΠΑΡΑΓΩΓΗΣ &amp; ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ
Angiox is contraindicated in patients with severe renal insufficiency (GFR &lt; 30 ml/min) and also in dialysis-dependent patients (see section 4.3).
Angiox je kontraindiciran u bolesnika s teškom bubrežnom insuficijencijom (GFR &lt; 30 ml/min), kao i u bolesnika koji ovise o dijalizi (vidjeti dio 4.3).
Angiox is contraindicated in patients with severe renal insufficiency (glomerular filtration rate (GFR) &lt; 30 ml/min) and in dialysis-dependent patients.
Angiox je kontraindiciran u bolesnika s ozbiljnom bubrežnom insuficijencijom (brzina glomerularne filtracije, GFR &lt; 30 ml/min) i bolesnika ovisnih o dijalizi .
Angiox is contraindicated in patients with severe renal insufficiency (glomerular filtration rate (GFR) &lt; 30 ml/min) and in dialysis-dependent patients.
Angiox je kontraindiciran u bolesnika s teškom bubrežnom insuficijencijom (brzina glomerularne filtracije, GFR &lt; 30 ml/min) i u bolesnika ovisnih o dijalizi.
Anidulafungin has negligible renal clearance ( &lt; 1%).
Bubrežni klirens anidulafungina je zanemariv ( &lt; 1%).
Anidulafungin is extensively bound ( &gt; 99%) to human plasma proteins.
Anidulafungin se velikim dijelom ( &gt; 99%) veže na proteine plazme.
Animal studies have shown a reduction in female fertility at high doses (systemic exposure &gt; 2.4 times the human exposure at the maximum recommended dose of 24 mg buprenorphine, based on AUC).
Ispitivanja na životinjama pokazala su smanjenje plodnosti ženki pri izloženosti visokim dozama (sistemska izloženost &gt; 2,4 puta od izloženosti ljudi pri maksimalnoj preporučenoj dozi od 24 mg buprenorfina, na temelju AUC).
Another patient had virus with Y93H at baseline and virologic failure and also developed low levels ( &lt; 5%) of NS5B NI RAVs N142T and E237G at failure.
Drugi je bolesnik imao virus s Y93H na početku ispitivanja i virološki neuspjeh te je također razvio niske razine ( &lt; 5 %) varijante NS5B povezane s rezistencijom na nukleozidne inhibitore N142T i E237G pri neuspjehu.
Anti-tumour activity was not observed in two studies among a total of 30 children aged &gt; 3 years old with relapsed or progressive high-grade glioma when treated with bevacizumab and irinotecan.
Antitumorska aktivnost nije opažena u dvije studije među ukupno 30-ero djece starijih od 3 godine s relapsnim ili progresivnim gliomom visokog stupnja malignosti, kada su liječena bevacizumabom i irinotekanom.
Antibody levels &gt; 100 IU/l should be maintained.
Potrebno je održavati razine antitijela &gt; 100 IU/l.
Antibody-mediated pure red cell aplasia has been very rarely reported in &lt; 1/10,000 cases per patient year after months to years of treatment with epoetin alfa (see section 4.4).
Izolirana aplazija crvene loze posredovana protutijelima zabilježena je vrlo rijetko u &lt; 1/10 000 slučajeva po bolesnik-godini nakon više mjeseci ili godina liječenja epoetinom alfa (vidjeti dio 4.4).
ap &lt; 0.0001 for assessment of non-inferiority to PRN
ap &lt; 0,0001 za procjenu neinferiornosti prema režimu p.p.
ap &lt; 0.0001 for comparisons of ranibizumab arms vs. laser arm. n in D2301-E1 (RESTORE Extension) is the number of patients with a value at both D2301 (RESTORE) baseline (Month 0) and at the Month 36 visit.
ap &lt; 0,0001 za usporedbe skupine koja je primala ranibizumab naspram skupine s laserskom terapijom. n u D2301-E1 (RESTORE Produžetak) označava broj bolesnika s vrijednošću na početku ispitivanja D2301 (RESTORE) (0. mjesec) i na posjetu u 36. mjesecu.
ap &lt; 0.0001for both studies
ap &lt; 0,0001 za oba ispitivanja
Apache II score  20
Apache II rezultat &gt; 20
Apparently meaningful symptom improvement (MID=2 point change in FKSI- DRS score; p &lt; 0.001) and time to improvement (HR= 1.66 (1.33,2.08), p &lt; 0.001) were significantly better for patients on the nivolumab arm.
Prividno značajno poboljšanje simptoma (minimalna važna razlika = promjena FKSI-DRS rezultata za 2 boda; p &lt; 0,001) i vrijeme do poboljšanja (HR = 1,66 [1,33; 2,08], p &lt; 0,001) bili su značajno bolji u bolesnika liječenih nivolumabom.
Approximately 25 % of patients treated with Taltz achieved a PASI score &lt; 5 by Week 2, more than 55 % achieved the PASI score &lt; 5 by Week 4, and increased to 85 % by Week 12 (compared to 3 %, 14 % and 50 % for etanercept).
Približno 25% bolesnika liječenih lijekom Taltz ostvarilo je PASI rezultat &lt; 5 do 2. tjedna, više od 55% njih ostvarilo je PASI rezultat &lt; 5 do 4. tjedna, a udio se povećao na 85% do 12. tjedna (u usporedbi s 3%, 14% odnosno 50% uz etanercept).
Approximately 40% and 14% of patients had mild (creatinine clearance ≥50 to &lt; 80 ml/min) or moderate (creatinine clearance ≥30 to &lt; 50 ml/min) renal impairment, respectively.
Oko 40% bolesnika imalo je blago (klirens kreatinina ≥50 do &lt; 80 ml/min), a oko 14% umjereno (klirens kreatinina ≥30 do &lt; 50 ml/min) oštećenje bubrega.
Approximately half of the patients who developed an ANC &lt; 1 x 109/ l did so within 8 weeks after starting therapy.
U približno polovice bolesnika koji su imali apsolutni broj neutrofila &lt; 1 x 109/ l smanjenje broja nastupilo je u roku od 8 tjedana od početka terapije.
Approximately one month after the toddler dose, the proportion of subjects in each group achieving this same antibody concentration threshold was &gt; 97%, except for serotype 3 (71% in preterm infants and 79% in term infants).
Otprilike mjesec dana nakon doze za malu djecu, udio ispitanika u svakoj skupini koji su postigli ovu istu graničnu vrijednost koncentracije protutijela bio je &gt; 97%, osim za serotip 3 (71% u prijevremeno rođene dojenčadi i 79% u dojenčadi rođene u terminu).
APV20002 is a 48 week, Phase II, open label study designed to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of fosamprenavir with and without ritonavir in paediatric subjects 4 weeks to &lt; 2 years of age.
APV20002 je faza II otvorenog ispitivanja u trajanju od 48 tjedana, osmišljena za procjenu farmakokinetike, sigurnosti, podnošljivosti i antivirusne aktivnosti fosamprenavira sa i bez ritonavira kod pedijatrijskih ispitanika u dobi od 4 tjedna &lt; 2 godine starosti.
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6- MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.: intravenous
Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6- merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.: intravenski
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count of  100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila &lt; 1,5 x 109/l i/ili broj trombocita &lt; 100 x 109/l
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count of  100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila &lt; 1,5 x 109/l i/ili broj trombocita &lt; 100 x 109/l.
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count of &lt; 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila &lt; 1,5 x 109/1 i/ili broj trombocita &lt; 100 x 109/1.
are breast-feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count of &lt; 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila &lt; 1,5 x 109/l i/ili broj trombocita &lt; 100 x 109/l.
are breast-feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count of &lt; 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, što se odnosi na početni broj neutrofila &lt; 1,5 x 109/l i/ili broj trombocita &lt; 100 x 109/l.
are breast-feeding (see section 4.6). already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils &lt; 1.5 x 109/l and/or a platelet count &lt; 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6). bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, što se odnosi na početni broj neutrofila &lt; 1,5 x 109/1 i/ili broj trombocita &lt; 100 x 109/1.
Are the Numbers 1, 2 &amp; 3 how I select my dose of medicine?
Određuju li brojevi 1, 2 i 3 način odabira doze lijeka?
ARICLAIM must not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min; see section 4.3).
ARICLAIM se ne smije primjenjivati u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina &lt; 30 ml/min; vidjeti dio 4.3).
Around 85% of patients had a viral load of &lt; 100,000 copies/ml.
Oko 85% bolesnika je imalo količinu virusa manju od 100.000 kopija/ml.
ART-experienced paediatric patients from the age of 3 to &lt; 6 years
Pedijatrijski bolesnici prethodno liječeni ART-om u dobi od 3 do &lt; 6 godina
ART-experienced paediatric patients from the age of 6 to &lt; 18 years and weighing at least 20 kg DELPHI is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of PREZISTA with low dose ritonavir in 80 ART-experienced HIV-1 infected paediatric patients aged 6 to 17 years and weighing at least 20 kg.
Pedijatrijski bolesnici prethodno liječeni ART-om u dobi od 6 do &lt; 18 godina i težine najmanje 20 kg DELPHI je otvoreno ispitivanje faze II, koje procjenjuje farmakokinetiku, sigurnost, podnošljivost i djelotvornost lijeka PREZISTA s niskom dozom ritonavira kod 80 pedijatrijskih bolesnika prethodno liječenih ART-om inficiranih s HIV-1, u dobi od 6 do 17 godina i težine najmanje 20 kilograma.
ART-experienced paediatric patients from the age of 6 to &lt; 18 years, and weighing at least 20 kg DELPHI is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of PREZISTA with low dose ritonavir in 80 ART-experienced HIV-1 infected paediatric patients aged 6 to 17 years and weighing at least 20 kg.
Pedijatrijski bolesnici prethodno liječeni ART-om u dobi od 6 do &lt; 18 godina i težine najmanje 20 kg DELPHI je otvoreno ispitivanje faze II, koje procjenjuje farmakokinetiku, sigurnost, podnošljivost i djelotvornost lijeka PREZISTA s niskom dozom ritonavira kod 80 pedijatrijskih bolesnika prethodno liječenih ART-om inficiranih s HIV-1, u dobi od 6 do 17 godina i težine najmanje 20 kilograma.
Arzerra was also given to a group of patients (n=112) with bulky lymphadenopathy (defined as at least one lymph node &gt; 5 cm) who were also refractory to fludarabine.
Arzerra je bila primijenjena i skupini bolesnika (n=112) s izraženijom limfadenopatijom (definiranom kao barem jedan limfni čvor &gt; 5cm), a koji također nisu reagirali na fludarabin.
As evaluated in a further study, in patients with a CrCl &lt; 60 ml/min the area under the curve was approximately 51% higher than in patients with a CrCl ≥60 ml/min, which suggests that a dose reduction of hydroxycarbamide by 50% may be appropriate in patients with a CrCl &lt; 60 ml/min.
Daljnjom je studijom procijenjeno da je kod bolesnika sa CrCl &lt; 60 ml/min površina ispod krivulje bila oko 51% viša nego kod bolesnika čiji je CrCl ≥ 60 ml/min, što upućuje na činjenicu da smanjivanje doze hidroksikarbamida za 50% može biti prikladno za bolesnike kod kojih je CrCl &lt; 60 ml/min.
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg funkcionalnog stanja (PS &gt; 1, engl. performance status) imaju slabiju stopu odgovora na liječenje i veću incidenciju komplikacija poput vrućice, infekcije i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg funkcionalnog stanja (PS &gt; 1, od engl. performance status) imaju manju stopu odgovora na liječenje i veću incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg općeg stanja (PS &gt; 1, od engl. performance status) imaju slabiji odgovor na liječenje i veću incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg općeg stanja (PS &gt; 1, od engl. performance status), pokazuju slabiji odgovor na liječenje i veću incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg funcionalnog stanja (PS &gt; 1, od engl. performance status) imaju slabiji odgovor na liječenje i veću incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg funkcionalnog stanja (PS &gt; 1, od engl. performance status) imaju slabiji odgovor na liječenje i veću incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As expected, patients with poor performance status (PS &gt; 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Prema očekivanjima, bolesnici slabijeg općeg stanja (PS &gt; 1, od engl. performance status) imaju slabiju stopu odgovora na liječenje i povećanu incidenciju komplikacija poput vrućice, infekcija i sepse (vidjeti dio 4.8).
As for other anticoagulants, fondaparinux should be used with caution in patients who have undergone recent surgery ( &lt; 3 days) and only once surgical haemostasis has been established.
Kao i ostale antikoagulanse, fondaparinuks treba primjenjivati uz oprez u bolesnika koji su nedavno podvrgnuti operativnom zahvatu ( &lt; 3 dana) i to tek nakon što je uspostavljena kirurška hemostaza.
As no quantifiable levels ( &gt; 5 ng/ml) of imiquimod are detected in the serum after single and multiple topical doses, no specific advice can be given on whether to use or not in lactating mothers.
Budući da nakon jednokratne ili višekratne lokalne primjene nije zabilježena mjerljiva razina ( &gt; 5 ng/ml) imikvimoda u serumu, ne može se donijeti adekvatan zaključak o uporabi kreme tijekom dojenja.
As renal impairment may be frequent in the elderly ( &gt; 75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment (i.e.
S obzirom da je oštećenje bubrega kod starijih osoba često ( &gt; 75 godina), bubrežna funkcija se procjenjuje tako da se izračuna CrCL prije početka liječenja Pradaxom kako bi se isključili bolesnici s teškim oštećenjem bubrega (tj.
As renal impairment may be frequent in the elderly ( &gt; 75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment (i.e.
S obzirom da je oštećenje bubrega kod starijih osoba često ( &gt; 75 godina), bubrežna funkcija se procjenjuje tako da se izračuna CrCL-a prije početka liječenja Pradaxom kako bi se isključili bolesnici s teškim oštećenjem bubrega (tj.
As renal impairment may be frequent in the elderly ( &gt; 75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment (i.e.
S obzirom na mogućnost čestog oštećenja bubrega kod starijih osoba ( &gt; 75 godina), bubrežna funkcija se ocjenjuje tako da se izračuna CrCL prije početka liječenja Pradaxom kako bi se isključili bolesnici s teškim oštećenjem bubrega (tj.
As systemic exposure is low with tacrolimus ointment, the high binding of tacrolimus ( &gt; 98.8%) to plasma proteins is considered not to be clinically relevant.
Budući da je sistemska izloženost takrolimusu iz masti niska, smatra se da visoka stopa vezanja takrolimusa za proteine plazme ( &gt; 98,8%) nije klinički značajan.
As the updated analysis is provided for descriptive purposes only, a p-value is not provided. b Hazard ratio (Xofigo over placebo) &lt; 1 favours Xofigo.
Budući da je ažurirana analiza prikazana samo u opisne svrhe, nije ponuđena p-vrijednost. b Omjer hazarda (Xofigo nad placebom) &lt; 1 u korist lijeka Xofigo.
As there is very limited clinical experience in patients with severe renal impairment (eGFR &lt; 30 ml/min/1.73 m2) (see section 5.1) Entresto should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.
Budući da postoji vrlo ograničeno kliničko iskustvo u bolesnika s teškim oštećenjem bubrega (eGFR &lt; 30 ml/min/1,73 m2) (vidjeti dio 5.1) Entresto treba primjenjivati s oprezom te se preporučuje početna doza od 24 mg/26 mg dvaput na dan.